Character Biosciences has raised $93m in an oversubscribed Series B funding round to expedite the progression of precision ...

The startup is bringing into Phase 1 testing an experimental treatment it says could be more effective than marketed ...

Character Biosciences is entering the clinic with a trove of company-generated human data already in hand. These data inform Character’s approach to targets for the dry form of age-related ...

To apply a precision medicine approach to this disease, Character Bio has partnered with over 150 ophthalmology treatment ...

A New Jersey-based biotech is looking to become the main character in the age-related macular degeneration field. | A New Jersey-based biotech is looking to become the main character in the ...

Character Biosciences has raised $93m in an oversubscribed Series B round to speed the clinical development of a pipeline of ...

Character Biosciences has raised $93m in an oversubscribed Series B funding round to expedite the progression of precision therapies for degenerative eye conditions, beginning with age-related ...

Funding will enable lead candidates CTX114 and CTX203 for AMD to enter clinical trials in the next year JERSEY CITY, N.J.--(BUSINESS WIRE)--Character Biosciences, a precision medicine company ...

Jersey City, N.J.-based Character Biosciences has raised $93 million in a series B financing round.  The funding will be used ...

Polygenic diseases company Character Biosciences has announced an oversubscribed $93 million Series B financing round to ...